Johnson & Johnson (JNJ)
163.12
-1.13 (-0.69%)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products
The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world.
HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.
Via Benzinga · March 18, 2025
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.
Via Benzinga · March 18, 2025
Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026.
Via Benzinga · March 18, 2025
Via The Motley Fool · March 18, 2025

Via Benzinga · March 10, 2025
Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.
Via MarketBeat · March 17, 2025
Amazing deals abound within Wall Street's benchmark index.
Via The Motley Fool · March 17, 2025
Large-cap stocks worst performers last week: TER, TTD, COIN, SAIL, GMAB, IBKR, DAL, ADBE, EXPE, HOOD, UAL, AAPL. Are they in your portfolio?
Via Benzinga · March 16, 2025
A lawsuit has been lodged against JPMorgan Chase by its employees, who claim that the company's prescription drug plan consented to pay exorbitant prices for medications.
Via Benzinga · March 15, 2025
Via The Motley Fool · March 14, 2025
Via The Motley Fool · March 14, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).
Via StockStory · March 14, 2025

When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But are high-yield stocks always the best route for income-focused investors? Let’s break it down.
Via Talk Markets · March 11, 2025

Via The Motley Fool · March 10, 2025

Vanguard has some excellent dividend ETFs, but they are right for different investors.
Via The Motley Fool · March 11, 2025

The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment.
Via Investor's Business Daily · March 10, 2025

Via Benzinga · March 10, 2025

Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints.
Via Benzinga · March 10, 2025

Via Benzinga · March 10, 2025

The market has thrown a tantrum over recent weeks following tariff news and other economic data pointing to a slowing consumer base. While it’s certainly been a turbulent period, several stocks have been able to shake off these market woes.
Via Talk Markets · March 9, 2025

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion
Via Benzinga · March 7, 2025

Two of the Dow Jones Industrial Average's 30 components make for no-brainer buys, while another brand-name member continues to suffer from self-inflicted wounds.
Via The Motley Fool · March 6, 2025

These ETFs have outperformed the market so far in 2025 but have lower asset bases than some of the most popular funds among investors.
Via MarketBeat · March 6, 2025